Clinical Trials Logo

Orbital Tumor clinical trials

View clinical trials related to Orbital Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT05613244 Completed - Orbital Tumor Clinical Trials

Descriptive Study of a Cohort of Orbital Solitary Fibrous Tumors

TFS-ORB
Start date: January 26, 2023
Phase:
Study type: Observational

Orbital solitary fibrous tumors are rare tumors with an intermediate potential of malignancy. Orbital solitary fibrous tumors' prognostic criteria are still poorly understood. Some patients with orbital solitary fibrous tumors have been treated at the Adolphe de Rothschild Foundation Hospital. This cohort will be studied to describe the recurrence rate and to identify predictive factors of recurrence or metastasis.

NCT ID: NCT04704414 Recruiting - Clinical trials for Graves Ophthalmopathy

Exophthalmometry With 3D Face Scanners

EX3D
Start date: August 14, 2019
Phase: N/A
Study type: Interventional

This study investigates diagnostic methods to measure eyeball protrusion with a smartphone face scanner compared to the traditional Hertel exophthalmometer. The study aims to validate a new reliable, fast and convenient smartphone app to measure the protrusion of the eyeball in different diseases such as Graves' disease, orbital tumors, orbital fractures or orbital inflammation, as well as other rare diseases.

NCT ID: NCT02434120 Completed - Orbital Tumor Clinical Trials

MRI Perfusion Curves Typology and Orbital Tumors (PERFORM)

PERFORM
Start date: November 2015
Phase:
Study type: Observational

Orbital masses develop at the expense of the orbital structures lacrimal glands, oculomotor muscles, optic nerve, meningeal spaces, peripheral nerves, bone wall, orbital fat, lymphoid structures or vascular structures. These masses can be tumors, benign or malignant, or pseudotumor, mainly represented by specific or non-specific orbital inflammation. Pathology is of considerable importance for the diagnosis and the treatment of those masses. However, biopsy or surgical resection of the orbital masses is sometimes difficult and dangerous outside expert centers. The identification of a non-invasive technique for distinguishing tumors from pseudotumors, thus avoid in some cases a biopsy, would be a major contribution for the patients. For salivary glands, MRI allows to identify 4 different types of MRI characteristics, one (type C) being related to malignant tumors. In this study, the investigators will try to see if extrapolation of those data to orbiltal tumors is feasible.

NCT ID: NCT02401906 Completed - Orbital Tumor Clinical Trials

MRI and Orbital Tumours (MEDORT)

MEDORT
Start date: May 27, 2015
Phase:
Study type: Observational

Orbital masses develop at the expense of the orbital structures lacrimal glands, oculomotor muscles, optic nerve, meningeal spaces, peripheral nerves, bone wall, orbital fat, lymphoid structures or vascular structures. These masses can be tumors, benign or malignant, or pseudotumor, mainly represented by specific or non-specific orbital inflammation. Pathology is of considerable importance for the diagnosis and the treatment of those masses. However, biopsy or surgical resection of the orbital masses is sometimes difficult and dangerous outside expert centers. The identification of a non-invasive technique for distinguishing tumors from pseudotumors, thus avoid in some cases a biopsy, would be a major contribution for the patients. The MRI assessment performed routinely in a patient with an orbital mass includes morphological sequences T1, T2 fat suppression, T1 injected fat suppression, diffusion. This exploration requires, regardless of the performed research, a contrast agent injection (0.1 mg / kg weight of Gadobutrol®). In this research protocol, during the injection of the contrast agent performed during the MRI assessment performed routinely, a DCE perfusion sequence, which consists of a repeated acquisition at short intervals of a volume gradient echo T1, will be added. This acquisition will be preceded by two short series for calibration. The post treatment will include parametric permeability cards (Ktrans) and plasmatic volume (Vp), evaluating one or more regions of interest in the tumor, normal lacrimal glands, jaw muscles and nasal mucosa being the reference. It will also be added a magnetic susceptibility EPI sequence type. All the qualitative parameters (T1, T2, T1 injected, distribution, low signal intensity in susceptibility) and quantitative (Ktrans, Vp, relative intensity enhancement, apparent diffusion coefficient) parameters will be collected. The result of the pathological exam of the biopsy or of the surgical specimen, which is the gold-standard, will be collected.